Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation

Amore, Davide; Pecoraro, Ylenia; Carillo, Carolina; Russo, Gianluca; Poggi, Camilla; Anile, Marco; Pagini, Andreina; Bassi, Massimiliano; Cagnetti, Sara; Mottola, Emilia; D’Agostino, Federica; Vannucci, Jacopo; Mantovani, Sara; Pugliese, Francesco; Giacomo, Tiziano De; Rendina, Erino Angelo; Venuta, Federico; Diso, Daniele

doi:10.1016/j.transproceed.2020.02.051

Cited by 6 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data for 169 patients treated with ceftazidimeavibactam from 17 case series (Table 4) were identified from the literature search [48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64]. One case series of three patients (Shields et al 2017 [65]) was excluded from the literature search results because clinical outcomes for these patients are included in another larger case series published by the same group (Shields et al 2016 [56]); data for the latter publication are summarised in Table 4.…”

Section: Case Series and Case Reportsmentioning

confidence: 99%

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

Introduction A systematic literature review was undertaken to evaluate real-world use of ceftazidime-avibactam for infections due to aerobic Gram-negative organisms in adults with limited treatment options. Methods Literature searches retrieved peer-reviewed publications and abstracts from major international infectious disease congresses from January 2015 to February 2021. Results were screened using pre-defined criteria to limit the dataset to relevant publications (notable exclusions were paediatric data and outcomes data for bacteria intrinsically resistant to ceftazidime-avibactam). Data for included publications were subjected to qualitative synthesis. Results Seventy-three relevant publications (62 peer-reviewed articles; 10 abstracts) comprising 1926 patients treated with ceftazidime-avibactam (either alone or combined with other antimicrobials) and 1114 comparator/control patients were identified. All patients were hospitalised for serious illness and most had multiple comorbidities. The most common infections were pneumonia, bacteraemia, and skin/soft tissue, urinary tract, or abdominal infections; smaller numbers of patients with meningitis, febrile neutropenia, osteomyelitis, and cystic fibrosis were also included. Carbapenem-resistant or carbapenemase-producing Enterobacterales (CRE; n = 1718) and carbapenem-resistant, multidrug-resistant (MDR), and extensively drug-resistant Pseudomonas aeruginosa ( n = 150) were the most common pathogens. Most publications reported positive outcomes for ceftazidime-avibactam treatment (clinical success rates ranged from 45 to 100% and reported 30-day mortality from 0 to 63%), which were statistically superior versus comparators in some studies. ceftazidime-avibactam resistance emergence occurred infrequently and mostly in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains. Conclusion This review provides qualitative evidence of successful use of ceftazidime-avibactam for the treatment of hospitalised patients with CRE and MDR P. aeruginosa infections with limited treatment options. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-021-00507-6.

show abstract

Section: Case Series and Case Reportsmentioning

confidence: 99%

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Newer antibiotics agents recommended based on mechanism of resistance and pathogen include Cefiderocol (CFDC), a novel siderophore cephalosporin; b-lactam-b-lactamase combinations such as ceftaizidime-avibactam (CAZ/ AVI), ceftolozane-tazobactam (C/T); and carbapenem-b-lactamase combinations meropenem-vaborbactam and imipenem-relebactam. Several studies and case reports describing the use of newer agents for the treatment of gram-negative infections in lung transplant are listed in (Table 2) [51][52][53][54][55][56][57][58].…”

Section: Multidrug-resistant Infectionsmentioning

confidence: 99%

The changing landscape of infections in the lung transplant recipient

Lum,

Koval

2024

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review Infections in lung transplant recipients remain a major challenge and can affect lung allograft function and cause significant morbidity and mortality. New strategies for the prevention and treatment of infection in lung transplantation have emerged and are reviewed. Recent findings For important vaccine preventable infections (VPIs), guidance has been updated for at risk solid organ transplant (SOT) recipients. However, data on the efficacy of newer vaccines in lung transplant, including the respiratory syncytial virus (RSV) vaccine, are limited. Studies demonstrate improved vaccination rate with Infectious Diseases consultation during pretransplant evaluation. Two new antiviral agents for the treatment and prevention of cytomegalovirus (CMV) in SOT, letermovir and maribavir, are bein incorporated into clinical care. CMV-specific cell-mediated immune function assays are more widely available. Antibiotics for the management of multidrug resistant pathogens and Burkholderia cepacia complex have been described in case series and case reports in lung transplant. Summary Although new vaccines and novel therapies for preventing and treating infections are available, larger studies evaluating efficacy in lung transplant recipients are needed.

show abstract

“…129 Experience with new BLBLIs among SOT recipients has been mainly restricted to case reports [145][146][147][148] and small series with no comparator group. 149,150 The SET/GESITRA-SEIMC/REIPI document did not make any mention of MER-VAB or IMI-REL and simply suggested-based on low-quality evidence (CIII)-that CAZ-AVI may be considered for the treatment of CRE infections if the strain shows in vitro susceptibility. 3 In…”

Section: New Blbli Combinationsmentioning

confidence: 99%

Extended‐spectrum β‐lactamase‐producing and carbapenem‐resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches

Pérez‐Nadales

2022

Transplant Infectious Dis

View full text Add to dashboard Cite

Background: Infections caused by multidrug-resistant gram-negative bacilli (MDR GNB), in particular extended-spectrum β-lactamase-producing (ESBL-E) and carbapenem-resistant Enterobacterales (CRE), pose a major threat in solid organ transplantation (SOT). Outcome prediction and therapy are challenging due to the scarcity of randomized clinical trials (RCTs) or well-designed observational studies focused on this population. Methods: Narrative review with a focus on the contributions provided by the ongoing multinational INCREMENT-SOT consortium (ClinicalTrials identifier NCT02852902) in the fields of epidemiology and clinical management. Results: The Spanish Society of Transplantation (SET), the Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC), and the Spanish Network for Research in Infectious Diseases (REIPI) recently published their recommendations for the management of MDR GNB Elena Pérez-Nadales and Mario Fernández-Ruiz contributed equally to this work.

show abstract

Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation

Cited by 6 publications

References 11 publications

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

The changing landscape of infections in the lung transplant recipient

Extended‐spectrum β‐lactamase‐producing and carbapenem‐resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches

Contact Info

Product

Resources

About